Suppr超能文献

靶向卵巢癌中的肿瘤微环境

Targeting the tumour microenvironment in ovarian cancer.

作者信息

Hansen Jean M, Coleman Robert L, Sood Anil K

机构信息

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX, USA.

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX, USA; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX, USA; Center for RNA Interference and Non-Coding RNA, University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX, USA.

出版信息

Eur J Cancer. 2016 Mar;56:131-143. doi: 10.1016/j.ejca.2015.12.016. Epub 2016 Feb 3.

Abstract

The study of cancer initiation, growth, and metastasis has traditionally been focused on cancer cells, and the view that they proliferate due to uncontrolled growth signalling owing to genetic derangements. However, uncontrolled growth in tumours cannot be explained solely by aberrations in cancer cells themselves. To fully understand the biological behaviour of tumours, it is essential to understand the microenvironment in which cancer cells exist, and how they manipulate the surrounding stroma to promote the malignant phenotype. Ovarian cancer is the leading cause of death from gynaecologic cancer worldwide. The majority of patients will have objective responses to standard tumour debulking surgery and platinum-taxane doublet chemotherapy, but most will experience disease recurrence and chemotherapy resistance. As such, a great deal of effort has been put forth to develop therapies that target the tumour microenvironment in ovarian cancer. Herein, we review the key components of the tumour microenvironment as they pertain to this disease, outline targeting opportunities and supporting evidence thus far, and discuss resistance to therapy.

摘要

癌症的起始、生长和转移研究传统上一直聚焦于癌细胞,认为癌细胞因基因紊乱导致生长信号失控而增殖。然而,肿瘤的失控生长不能仅用癌细胞自身的畸变来解释。要全面了解肿瘤的生物学行为,必须了解癌细胞所处的微环境,以及它们如何操纵周围基质以促进恶性表型。卵巢癌是全球妇科癌症死亡的主要原因。大多数患者对标准的肿瘤减瘤手术和铂类 - 紫杉烷双联化疗会有客观反应,但大多数患者会经历疾病复发和化疗耐药。因此,人们付出了巨大努力来开发针对卵巢癌肿瘤微环境的疗法。在此,我们综述与该疾病相关的肿瘤微环境的关键组成部分,概述目前的靶向机会和支持证据,并讨论治疗耐药性。

相似文献

1
Targeting the tumour microenvironment in ovarian cancer.靶向卵巢癌中的肿瘤微环境
Eur J Cancer. 2016 Mar;56:131-143. doi: 10.1016/j.ejca.2015.12.016. Epub 2016 Feb 3.
2
Epithelial ovarian cancer: focus on targeted therapy.上皮性卵巢癌:聚焦于靶向治疗。
Crit Rev Oncol Hematol. 2011 Jul;79(1):17-23. doi: 10.1016/j.critrevonc.2010.07.004. Epub 2010 Aug 2.
5
Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.曲贝替定(AMG 386)治疗上皮性卵巢癌的疗效。
Expert Opin Pharmacother. 2016;17(6):853-60. doi: 10.1517/14656566.2016.1161027. Epub 2016 Mar 21.
10
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.上皮性卵巢癌的维持治疗:从化疗到靶向药物
Expert Rev Anticancer Ther. 2014 Sep;14(9):1041-50. doi: 10.1586/14737140.2014.922415. Epub 2014 Jun 23.

引用本文的文献

6
Diagnostic, prognostic, and immunological roles of CDSN in ovarian cancer.CDSN在卵巢癌中的诊断、预后及免疫作用
Heliyon. 2024 Jun 21;10(12):e33357. doi: 10.1016/j.heliyon.2024.e33357. eCollection 2024 Jun 30.
10
Antidiabetic Drugs in Breast Cancer Patients.乳腺癌患者中的抗糖尿病药物。
Cancers (Basel). 2024 Jan 10;16(2):299. doi: 10.3390/cancers16020299.

本文引用的文献

3
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
4
Cancer statistics, 2015.癌症统计数据,2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
7
Incorporation of pazopanib in maintenance therapy of ovarian cancer.将帕唑帕尼纳入卵巢癌维持治疗。
J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验